South and Central America Brain Cancer Diagnostics Market Growth and Recent Trends by 2028

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

South and Central America Brain Cancer Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Diagnostic Type (Imaging Test, Lumbar Puncture, Biopsy, Molecular Testing, and Others); Cancer Type (Acoustic Neuroma, Astrocytoma, Craniopharyngiomas, Ganglioneuromas, Glioblastoma Multiforme, Meningiomas, Ependymomas, and Others); End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others)

  • Report Date : Nov 2021
  • Report Code : TIPRE00025906
  • Category : Life Sciences
  • Status : Published
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 145
Page Updated: Nov 2021

The brain cancer diagnostics market in South and Central America is expected to grow from US$ 69.7 million in 2021 to US$ 175.8 million by 2028; it is estimated to grow at a CAGR of 14.1% from 2021 to 2028.

Currently, there is insufficient evidence that they are less harmful than traditional cigarettes. Researchers at Wake Forest School of Medicine have discovered that nicotine promotes the spread of lung cancer cells to the brain, thereby forming deadly metastatic tumors. The study, published in the Journal of Experimental Medicine (JEM), suggests that nicotine replacement therapy may not be suitable for lung cancer patients trying to quit smoking. Thus, the increase in the number of cigarette smokers is bolstering the growth of the brain cancer diagnostics market.   

The COVID‐ 19 pandemic is a critical test for the already overburdened and underfunded public healthcare systems of South and Central America. It suffers from severe inequalities. With a vast population living in poverty, South and Central America continuously face widespread health problems due to overcrowding, limited sanitation, food insecurity, and unpredictable environmental conditions. Underfunded state‐run hospitals are the only source of medical care in the region. Brazil is in a critical situation due to COVID-1. Lack of resources is creating more challenges in the region, hampering the growth of the brain cancer diagnostics market. All these factors will restrict the distribution and adoption of diagnostics products and services which will restrict the market growth. However, as the vaccination continues to these countries, the various market players in this region will again start focusing on development of brain cancer diagnostics and increase their distribution of products. Hence impact of pandemic will become moderated on the brain cancer diagnostics market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the brain cancer diagnostics market. The South and Central America brain cancer diagnostics market is expected to grow at a good CAGR during the forecast period.

South and Central America brain cancer diagnostics market

  • This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

South and Central America Brain Cancer Diagnostics Market Segmentation 

By Diagnostic Type

  • Imaging Test
    • MRI
    • CT Scan
    • PET
  • Biopsy
  • Molecular Testing
  • Lumbar Puncture
  • Others

By Cancer Type

  • Glioblastoma Multiforme
  • Astrocytomas
  • Ependymomas
  • Others

By End User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others

By Country

  • South and Central America
    • Brazil
    • Argentina
    • Rest of South and Central America

Companies Mentioned

  1. Thermo Fisher Scientific Inc.
  2. Siemens Healthineers A
  3. GE Healthcare
  4. Biocept, Inc.
  5. Koninklijke Philips N.V
  6. Canon Medical Systems
  7. Hitachi, Ltd.
  8. Neusoft Medical Systems

South and Central America Brain Cancer Diagnostics Report Scope

Report Attribute Details
Market size in 2021 US$ 69.7 Million
Market Size by 2028 US$ 175.8 Million
Global CAGR (2021 - 2028) 14.1%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Diagnostic Type
  • Imaging Test
  • Lumbar Puncture
  • Biopsy
  • Molecular Testing
By Cancer Type
  • Acoustic Neuroma
  • Astrocytoma
  • Craniopharyngiomas
  • Ganglioneuromas
  • Glioblastoma Multiforme
  • Meningiomas
  • Ependymomas
By End User
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
Regions and Countries Covered South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Market leaders and key company profiles
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers A
  • GE Healthcare
  • Biocept, Inc.
  • Koninklijke Philips N.V
  • Canon Medical Systems
  • Hitachi, Ltd.
  • Neusoft Medical Systems
Mrinal Kerhalkar
Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

  • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
  • PEST and SWOT Analysis
  • Market Size Value / Volume - Global, Regional, Country
  • Industry and Competitive Landscape
  • Excel Dataset

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Our Clients
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
Email: sales@theinsightpartners.com
Chat with us
DUNS Logo
87-673-9708
ISO Certified Logo
ISO 9001:2015
ISO Certified Logo